Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.55 |
| ▸ | POLG | P54098 | 2/20 | 0.54 |
| ▸ | PNP | P00491 | 2/20 | 0.53 |
| ▸ | FUT5 | Q11128 | 1/20 | 0.52 |
| ▸ | TGM2 | P21980 | 1/20 | 0.52 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.52 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.52 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.52 |
| ▸ | HPRT1 | P00492 | 6/20 | 0.49 |
| ▸ | KRAS | P01116 | 2/20 | 0.49 |
| ▸ | NT5E | P21589 | 1/20 | 0.47 |
| ▸ | POLA1 | P09884 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19662102 | 0.88 | POLB (0.66) | POLBPOLGPNPFUT5TGM2 | |
| SCHEMBL23358376 | 0.86 | POLG (0.59) | POLBPOLGPNPFUT5TGM2 | |
| SCHEMBL1913809 | 0.84 | TGM2 (0.62) | POLBPOLGPNPFUT5TGM2 | |
| SCHEMBL25712474 | 0.84 | TGM2 (0.62) | POLBPOLGPNPFUT5TGM2 | |
| SCHEMBL7065119 | 0.84 | TGM2 (0.62) | POLBPOLGPNPFUT5TGM2 | |
| SCHEMBL5334255 | 0.84 | FUT5 (0.58) | POLBPOLGPNPFUT5TGM2 | |
| SCHEMBL5326405 | 0.83 | FUT5 (0.57) | POLBPOLGPNPFUT5TGM2 | |
| SCHEMBL22475042 | 0.83 | FUT5 (0.64) | POLBPOLGPNPFUT5TGM2 | |
| SCHEMBL23584319 | 0.83 | FUT5 (0.64) | POLBPOLGPNPFUT5TGM2 | |
| SCHEMBL15833359 | 0.83 | FUT5 (0.64) | POLBPOLGPNPFUT5TGM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10906930-B2 | Compositions and methods for activating “stimulator of interferon gene”-dependent signalling | CHINOOK THERAPEUTICS, INC. (US) | 2021-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10906930-B2 | Compositions and methods for activating “stimulator of interferon gene”-dependent signalling | STING1, IRF3, CGAS | POLB 1121/4885POLG 1058/4885PNP 454/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.